×

Meet the team @

BioEurope, Barcelona

Gateway to
Johnson & Johnson Innovation, JLINX

ENTER

Working apart together. That is what we do.

Bioqube ventures has one mission: bringing early-stage healthcare companies to the next level. Entrepreneurial, result driven, shoulder to shoulder.

Our team jointly represents over 40 years of leadership experience in identifying and funding promising scientific opportunities, is skilled in helping businesses grow and is deeply connected across corporate, government and academic research ecosystems.

We cut cost, accelerate business and bring value by linking three key components: access to capital, specialized infrastructure and expertise.

Our partnership with Johnson & Johnson Innovation – JLINX, is the embodiment of our mission: a multifaceted approach that enables early-stage healthcare companies to reach their full potential in a cost effective and time efficient way. Whether you are a scientist, entrepreneur or venture capitalist, bioqube ventures will face the challenge – working apart, and together with you.

Nico Vandervelpen

Nico Vandervelpen MSc

Managing Partner

Nico Vandervelpen is managing director and co-founder of bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to act as the independent management arm leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, bioqube ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies, and supporting the overall scale-up of the new initiative.

Nico previously served in a variety of capacities at LRM, a Belgium-based private equity and venture capital firm, including most recently as the funds Chief Operating Officer. Prior to joining LRM, between 1998 and 2007, Nico was a senior executive at Ernst & Young.

Nico served on the board of directors of several public and private life sciences companies and has led several dozen international venture capital transactions and M&A deals including Minerva Neurosciences (Nasdaq: NERV), Tigenix (NYSE Euronext: TIG), SEPS Pharma (acquired by Amatsi) and Apitope. Nico holds a Masters degree in commercial and business engineering from Hasselt University as well as a Master in Accountancy from VLEKHO Business School - Brussels.

nico@bioqubeventures.com

Debora Dumont

Debora Dumont PhD

Managing Partner

Debora Dumont is managing director and cofounder of bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to act as the independent management team leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, bioqube ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies and supporting the overall scale-up of the new initiative.

Debora previously served as Head of Health & Care at LRM, a Belgium-based private equity and venture capital firm. In this position, she served as a board member on several biotech companies and was involved in a series of international venture capital transactions including XO1 (acquired by Johnson & Johnson), FFPharma, Complix and Therasolve. Prior to joining LRM, between 2007 and 2010, Debora was a business developer at the Biomedical Research Institute of Hasselt University and manager of the life sciences cluster organization LifeTechLimburg (now LifeTechValley).

Debora has a PhD in Biomedical Sciences from Hasselt University and holds a Masters degree in Bioscience Engineering from K.U. Leuven.

debbie@bioqubeventures.com

Tol Trimborn

Tol Trimborn PhD

Venture Partner

Tol Trimborn is a Venture Partner of bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to act as the independent management team leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, bioqube ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies, and supporting the overall scale-up of the new initiative.

Tol has over 15 years of experience in the life sciences and venture capital industry. He is a highly motivated, creative and dynamic entrepreneur. Tol serves and has served in a variety of management capacities, including CEO of Arcarios, COO of Gadeta, founder and general manager at DNage (acquired by Pharming). He has co-founded several companies including Arcarios and Gadeta.

Tol started his career as a Postdoctoral fellow conducting scientific research at the prestigious Howard Hughes Medical Institute of Stanford, became a leader of the molecular biology activities at Kalobios, an early-stage biotech start-up in Mountain View and expanded his scientific network into a commercially oriented network as a biotech analyst at LSP, The Netherlands.

Tol has a PhD in Medical Biology at the Erasmus University Rotterdam, The Netherlands and holds Masters degrees in biology and chemistry from Leiden University, The Netherlands.

tol@bioqubeventures.com

Dirk Reyn

Dirk Reyn Ph MBA

Venture Coach

Dirk Reyn is a Venture Coach of bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson to act as the independent management team leading the new Johnson & Johnson Innovation, JLINX initiative.

Dirk has over 30 years of experience in the life sciences industry. He has served in a variety of management capacities, including Global Business Unit leader for Gastroenterology, head of a Regulatory department and head of European Business development at JNJ, Founder and CEO of Movetis, Global Commercial lead at Shire, founder and CEO of Progress Pharma and founder of R&S consulting. He is currently CEO of ETheRNA, a spin-off from the University of Brussels with a breakthrough therapy for cancer. He is also board member of Tigenix and vice-chairman of Flandersbio, an organization of Flemish biotech companies.

Dirk Reyn is a Pharmacist and has an MBA from Handelshogeschool (Antwerpen)/Northwestern University (Kellog’s Chicago/USA).

dirk@bioqubeventures.com

Joris De Maeyer

Joris De Maeyer PhD

Venture Coach

Joris is a Venture Coach of Bioqube Ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson to act as the independent management team leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, bioqube ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies and supporting the overall scale-up of the new initiative.

Joris has 15 years' experience in the pharma-biotech sector, shaping and directing innovative and collaborative R&D programs. As an independent advisor, Joris currently provides strategic R&D and funding advise to international biotech companies and acts as Director R&D at Facio Therapies. Previously, Joris had various roles of increasing responsibility in start-ups as well as in large international companies such as Johnson & Johnson, Movetis and Shire Pharmaceuticals, where in his most recent position he served as Director Discovery.

Joris holds a PhD in Medical Sciences from Ghent University and a Masters in Bioscience Engineering from the Catholic University of Leuven.

joris@bioqubeventures.com

Kris Motmans

Kris Motmans PhD

Venture Coach

Kris Motmans is a Venture Coach at bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson to act as the independent management team leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, bioqube ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies and supporting the overall scale-up of the new initiative.

Kris has over 15 years of experience in the life sciences and financial industry. As a corporate development advisor he held and holds several advisory, management and director mandates in private and public biomedical companies including Beta-Cell, Apitope, SEPS Pharma (acquired by Amatsi) and TiGenix (NYSE Euronext: TIG). Kris has also been acting as sector specialist for a number of investment boutiques and venture capital firms such as Puilaetco Bankers, Bryan Garnier, Kepler Equities and LRM where he was involved in the identification, execution and/or follow-up of private and public financing transactions. Between 2009 and 2014, Kris acted as manager of BioVille, the life scienes incubator from LRM, a regional venture capital and development firm.

Kris has a PhD in Medical Sciences from Hasselt University and holds a Masters degree in chemistry from Ghent University. He started his scientific career as a Postdoctoral fellow at the Longwood Medical Research Center, Harvard Medical School and Head of oncology at Hasselt University. Kris gained industry experience as patent and licensing manager at Johnson & Johnson and expanded his expertise in the financial sector as equity analyst and fund manager for Puilaetco Bankers.

kris@bioqubeventures.com

Kris Motmans

Heleen Castelyns BBa

Office Manager

Heleen Castelyns is Office Manager at bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to act as the independent management team leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, bioqube ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies and supporting the overall scale-up of the new initiative.

Heleen previously served as Payroll Administrator at Janssen Pharmaceutica, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, based in Beerse. Prior to joining Janssen Pharmaceutica, between 2010 and 2013, Heleen was a HR Generalist at Movetis NV, a European specialty GI company, and Management Assistant at Janssen Pharmaceutica.

Heleen has a Bachelor Degree in Office Management from Katholieke Hogeschool Kempen in Turnhout.

heleen@bioqubeventures.com

Bioqube ventures
gateway to Johnson & Johnson Innovation, JLINX

We can’t wait hearing how you could fit in.

About JLINX

Johnson & Johnson Innovation’s mission is to identify the best science around the world to advance important therapies and products for patients and consumers. To support its mission, Johnson & Johnson is expanding its company incubation strategy with the launch of Johnson & Johnson Innovation, JLINX, an investment and incubation model, involving bioqube ventures as an external management team, hosted in a fully dedicated facility located on the Janssen Research & Development Campus in Beerse, Belgium.

JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment for scientist entrepreneurs to access capital, infrastructure, resources and expertise needed to build their businesses and advance scientific research and development for the benefit of patients.

The power of the JLINX model lies in the ambition of trying to marry internal expertise with external entrepreneurial skills and hence creating a start-up culture with selected resources, insights and expertise of a global healthcare leader to accelerate breakthroughs.

Investment in promising transformative innovation through the JLINX initiative is venture-based and will not hold any specific rights to commercialized products. JLINX will launch with initial venture funding from Johnson & Johnson Innovation, JJDC (JJDC) with the aim to leverage these funds along with those from additional external investors.

Visit jlinx.jnjinnovation.com for more information about JLINX.

JLINX is supported by the European Union through the European Regional Development Fund and by the Flemish Government through Flanders Innovation & Entrepreneurship.

Newsroom

S-Biomedic joins the JLINX Community
Read more

Caelus Health joins the JLINX Community
Read more

Octimet Oncology joins the JLINX Community
Read more

eTheRNA joins the JLINX Community
Read more

"Pitch your Microbes" – Meet our winners: S-Biomedic and BioMillenia!!
Pitch your Microbes Winners

Bioqube Ventures teams up with Johnson & Johnson Innovation, JLINX and Janssen Human Microbiome Institute - "Pitch Your Microbes" Competition
Read more

Bioqube Ventures expands team with Ventures Coaches
Meet the team

JLINX Launch Event – Sparking Life Science Innovation - Beerse Belgium

Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium
Read more

Bioqube ventures launches specialist investment firm and announces collaboration with Johnson & Johnson Innovation, JLINX
Read more

Events

Contact

General & Investor Enquiries:
info@bioqubeventures
+32 477 66 42 49

Media Enquiries:
Hume Brophy
Mary Clark, Supriya Mathur
bioqube@humebrophy.com
+44 (0)20 7862 6475

Hasselt Office
Runkstersteenweg 211/2
3500 Hasselt, Belgium
Antwerp Office
Turnhoutseweg 30
2340 Beerse, Belgium

 


London Office
Johnson & Johnson Innovation Centre
One Chapel Place
Marylebone, London W1G 0JB